Document is current
Any future updates will be listed below
-
Authors
Green, Rhiannon https://orcid.org/0000-0001-6113-0675
Marjenberg, Zoe
Lip, Gregory Y. H.
Banerjee, Amitava https://orcid.org/0000-0001-8741-3411
Wisnivesky, Juan
Delaney, Brendan C. https://orcid.org/0000-0002-3518-0131
Peluso, Michael J. https://orcid.org/0000-0003-0585-6230
Wynberg, Elke
Abduljawad, Sultan https://orcid.org/0000-0001-5298-7749
-
Funding
Funding for this research was provided by:
BioNTech
- License Information
-
More Information
Article History
Received: 20 November 2024
Accepted: 10 October 2025
First Online: 24 November 2025
Competing interests
: S.A. is an employee of BioNTech SE. R.G. and Z.M. are employees of Maverex Ltd both of whom received consulting fees from BioNTech SE. G.Y.H.L.: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Anthos. No fees were received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator. M.J.P. has received consulting fees from Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech and research support from Aerium Therapeutics and Shionogi, outside the submitted work. A.B.: Consultant for Perspectum. Speaker for Shionogi and Pfizer. J.W. has received honorarium from Banook, PPD, BioNTech, AMA, and Sanofi and research grants from Sanofi, Regeneron, and Boehringer Ingelheim. B.C.D.: BioNTech—one-off advisory board on long COVID in 2024. E.W. has received financial compensation from BioNTech.
